Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (NASDAQ: DRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage oncology therapeutics company developing the Alpha DaRT alpha-radiation therapy for solid tumors.
Through these filings, investors can review information that Alpha Tau has furnished about its operations, clinical development, and financial position. Recent Form 6-K reports have attached press releases covering topics such as third quarter financial results and corporate updates, receipt of a radioactive material license for the New Hampshire manufacturing facility, and participation in major healthcare conferences. These documents also indicate how certain reports and exhibits are incorporated by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8.
For those analyzing DRTS, the filings are a primary source for details on research and development spending, marketing and general and administrative expenses, net losses, cash and deposits, property and equipment, lease liabilities, warrants, and shareholders’ equity. They also outline risk factors and other considerations referenced in the company’s Form 20-F and related registration statements.
On Stock Titan, users can view Alpha Tau’s SEC submissions as they are made available from EDGAR and use AI-powered summaries to interpret lengthy documents such as financial statements and exhibits. This helps readers quickly understand key points about Alpha Tau’s clinical-stage business model, funding position, and regulatory reporting without manually parsing every line of each filing.
Alpha Tau Medical reported a larger net loss for 2025 while advancing its Alpha DaRT cancer therapy and strengthening its balance sheet. The company posted a 2025 net loss of $42.6 million, or $0.53 per share, compared with a $31.8 million loss, or $0.45 per share, in 2024, driven mainly by higher research and development and general and administrative costs.
R&D expenses rose to $32.1 million from $27.0 million, and G&A increased to $8.4 million from $6.7 million, while marketing expenses declined slightly. Despite the wider loss, cash, cash equivalents, short-term deposits and restricted deposits increased to $76.9 million as of December 31, 2025, up from $62.9 million a year earlier, supporting ongoing trials and commercial preparations. Recent milestones include Japanese marketing approval for Alpha DaRT, a fifth parallel U.S. trial approval, first brain cancer treatment using Alpha DaRT, and progress across pancreatic and glioblastoma studies.
Alpha Tau Medical Ltd. files its annual Form 20‑F as a clinical‑stage oncology company developing its Alpha DaRT local alpha‑radiation technology for solid tumors. The company has no product revenue and reported net losses of $31,750 and $42,627 for the years ended December 31, 2024 and 2025, respectively, with an accumulated deficit of $190,136 as of December 31, 2025.
As of that date, Alpha Tau had 88,009,737 ordinary shares outstanding. In April 2025 it sold 14,110,121 ordinary shares to Oramed Ltd. at $2.612 per share, generating net proceeds of about $36.7 million, and believes existing cash should fund operations for at least the next two years. The filing emphasizes extensive risks around ongoing losses, future funding needs, stringent global device regulation, clinical trial uncertainty and potential product liability as it seeks marketing authorization for Alpha DaRT across multiple cancer indications.
DRTS submitted a Form 144 notice identifying a proposed sale of 10,000 ordinary shares through Oppenheimer & Co. Inc.
The filing also lists 87,500 restricted stock units dated 08/08/2021 and records a prior sale by Levy Raphi of 60,000 ordinary shares on 01/08/2026 for $404,674.46.
Alpha Tau Medical Ltd. reported that Japan’s Ministry of Health, Labour and Welfare has granted Shonin marketing approval for its Alpha DaRT® therapy to treat unresectable locally advanced or locally recurrent head and neck cancer. This is the first regulatory approval for the Alpha DaRT platform outside Israel.
As a condition of approval, the company will run a post-market surveillance study in Japan, enrolling 66 patients across five leading clinical centers to further evaluate safety and clinical performance. Alpha Tau and its partner HekaBio are preparing for launch and plan discussions with Japanese authorities about potential reimbursement and additional clinical studies in other tumor types.
An insider has filed a notice of proposed sale under Rule 144 to sell 87,010 ordinary shares through Oppenheimer & Co. Inc. on or about 02/02/2026, with the shares listed on Nasdaq. The aggregate market value of this planned sale is stated as 603,849.40, based on the figures in the notice.
The insider, identified as Gat Amnon, previously sold ordinary shares of the same issuer during the past three months. These earlier sales were 16,000 shares on 11/03/2025 for 62,404.91, 33,351 shares on 12/01/2025 for 148,918.59, and 90,559 shares on 01/02/2026 for 549,741.24. The shares to be sold were originally acquired on 02/21/2017 through an employee stock option plan, with cash payment upon exercise.
Alpha Tau Medical Ltd. provides a detailed update on its Alpha DaRT cancer therapy program, highlighting an expectedly active 2026 with multiple clinical and regulatory milestones. The company now has five concurrently approved trials in the U.S., alongside studies in Europe, Japan and Israel.
Management targets completion of patient recruitment in the IMPACT pancreatic cancer study by the end of Q1 2026, with initial results around year end. A U.S. glioblastoma trial has begun dosing, with plans to enroll ten patients and aim for initial data around the end of 2026, subject to safety review and site expansion.
The company anticipates a regulatory decision in Japan for recurrent head and neck cancer and is progressing its ReSTART pivotal skin cancer trial, expecting to complete enrollment this quarter and finish Modular PMA submission to the FDA toward year end. Alpha Tau continues to ramp manufacturing in Israel and the U.S., build out its New Hampshire facility, invest in automation, and expand intellectual property with dozens of new patent applications and grants while describing its cash burn as stable.
A holder of ordinary shares of issuer DRTS, identified as Raphi Levy, filed a Rule 144 notice to sell 15,000 ordinary shares through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $106,350.00. The notice states that 70,380,570 ordinary shares were outstanding and that the shares to be sold were originally acquired as 87,500 restricted stock units from the issuer on 08/08/2021.
Over the prior three months, the same seller reported additional sales of ordinary shares: 20,000 shares on 01/08/2026 for gross proceeds of $122,100.00, 10,000 shares on 01/09/2026 for $69,000.00, 10,600 shares on 01/12/2026 for $74,260.00, and 4,400 shares on 01/13/2026 for $31,240.00.
An insider, Levy Raphi, has filed a notice of proposed sale of 25,000 ordinary shares of the issuer through Oppenheimer & Co. Inc. on Nasdaq, with an indicated aggregate market value of 160,250.00. The filing states that 70,380,570 ordinary shares were outstanding at the time of the notice.
The securities to be sold were originally acquired as 70,000 restricted stock units (RSUs) from the issuer on 08/08/2021. Over the past three months, the same seller has already sold 20,000 ordinary shares on 01/08/2026 for gross proceeds of 121,650.00. By signing the notice, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s operations.
Form 144 for DRTS reports a planned sale of ordinary shares. The notice covers 61,745 ordinary shares to be sold through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $364,295.50 and 70,380,570 shares outstanding. The shares to be sold were acquired on 02/21/2017 under an employee stock option plan from the issuer, with cash paid upon exercise.
Over the prior three months, the filer, Gat Amnon, sold additional ordinary shares of the same issuer: 16,000 shares on 11/03/2025 for $62,404.91, 33,351 shares on 12/01/2025 for $148,918.59, and 33,351 shares on 01/02/2026 for $166,120.25. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of ordinary shares of DRTS has filed a notice of proposed sale under Rule 144. The filing states an intention to sell 20,000 ordinary shares through Oppenheimer & Co. Inc. on the Nasdaq market, with an aggregate market value of $118,000. These shares are part of 70,000 restricted stock units (RSUs) that were acquired from the issuer on 08/08/2021. The notice also reports that there were 70,380,570 shares of this class outstanding, providing a sense of the company’s total equity base.